Equities Analysts Issue Forecasts for KYMR FY2029 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for Kymera Therapeutics in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will post earnings per share of ($6.44) for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same period last year, the company earned ($0.90) EPS. The company’s quarterly revenue was down 20.9% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Oppenheimer raised their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Guggenheim boosted their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, UBS Group dropped their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.38.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $40.52 on Wednesday. The firm has a 50-day simple moving average of $44.08 and a two-hundred day simple moving average of $43.89. The stock has a market cap of $2.62 billion, a PE ratio of -17.32 and a beta of 2.19. Kymera Therapeutics has a 1-year low of $25.46 and a 1-year high of $53.27.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics in the 3rd quarter valued at $61,000. Quarry LP purchased a new stake in Kymera Therapeutics in the third quarter valued at $95,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in shares of Kymera Therapeutics during the second quarter worth about $139,000. Finally, Quest Partners LLC increased its position in shares of Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after purchasing an additional 4,865 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.